Early development of castrate resistance varies with different dosing regimens of luteinizing hormone releasing hormone agonist in primary hormonal therapy for prostate cancer

Urology

Volumn 77, Issue 2, 2011, Pages 412-416

  Blumberg, Jeremy M ^a   Kwon, Eric O ^a   Cheetham, T Craig ^a   Niu, Fang ^a   Shapiro, Charles E ^a   Pacificar, Judith ^a   Loo, Ronald K ^a   Williams, Stephen G ^a   Chien, Gary W ^a  

^a KAISER PERMANENTE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

AGED; ARTICLE; CANCER REGISTRY; DOSAGE SCHEDULE COMPARISON; GLEASON SCORE; HAZARD RATIO; HORMONAL THERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT FAILURE;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG RESISTANCE, NEOPLASM; GONADOTROPIN-RELEASING HORMONE; HUMANS; LEUPROLIDE; MALE; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 79551613091     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2010.08.037     Document Type: Article

References (13)

1. C. Huggins, and C.V. Hodges Studies on prostate cancer: the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate Cancer Res 1 1941 293 297
2. S.L. Goldenberg, N. Bruchovsky, and M.E. Gleave Intermittent androgen suppression in the treatment of prostate cancer: a preliminary report Urology 45 1995 839 845
3. N. Sato, K. Akakura, S. Isaka Chiba Prostate Study Group Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study Urology 64 2004 341 345
4. A.S. Pathak, J.S. Pacificar, and C.E. Shapiro Determining dosing intervals for luteinizing hormone releasing hormone agonists based on serum testosterone levels: A prospective study J Urol 177 2007 2132 2135
5. R. Sharifi, R.C. Bruskewitz, and M.C. Gittleman Leuprolide acetate;22.5mg 12-week depot formulation in the treatment of patients with advanced prostate cancer Clin Ther 18 1996 647 657
6. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974 (Pubitemid 28445094)
7. J. de Leval, P. Boca, and E. Yousef Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-nave prostate cancer: results of a prospective randomized multicenter trial Clin Prostate Cancer 1 2002 163 171
8. N. Bruchovsky, L. Klotz, and J. Crook Final results of the Canadian prospective phase 2 trial of intermittent androgen suppression for men in biochemical recurrence after radiotherapy for locally advanced prostate cancer Cancer 107 2006 389 395
9. A.J. Salonen, J. Viitanen, S. Lundstedt FinnProstate Group Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation J Urol 180 2008 915 920
10. M.G. Oefelein, and R. Curnum Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm J Urol 164 2000 726 729
11. M.G. Oefelein Health related quality of life using serum testosterone as the trigger to re-dose long acting depot luteinizing hormone-releasing hormone agonists in patients with prostate cancer J Urol 169 2003 251 255
12. K. Akakura, N. Bruchovsky, and S.L. Goldenberg Effects of intermittent androgen suppression on androgen-dependent tumors Apoptosis and serum prostate-specific antigen Cancer 71 1993 2782 2790
13. N. Sato, E.G. Martin, and N. Bruchovsky Intermittent androgen suppression delays progression to androgen-independent regulation of prostate-specific antigen gen in the LNCaP prostate tumor model J Steroid Biochem Mol Biol 58 1996 139 146 (Pubitemid 26284510)